Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Retained Earnings (2020 - 2025)

Apellis Pharmaceuticals (APLS) has 6 years of Retained Earnings data on record, last reported at -$3.0 billion in Q4 2025.

  • For Q4 2025, Retained Earnings fell 90981.56% year-over-year to -$3.0 billion; the TTM value through Dec 2025 reached -$3.0 billion, down 90981.56%, while the annual FY2025 figure was -$3.0 billion, 90981.56% down from the prior year.
  • Retained Earnings reached -$3.0 billion in Q4 2025 per APLS's latest filing, roughly flat from -$3.0 billion in the prior quarter.
  • Across five years, Retained Earnings topped out at -$796000.0 in Q2 2023 and bottomed at -$3.2 billion in Q2 2025.
  • Average Retained Earnings over 5 years is -$1.6 billion, with a median of -$2.0 billion recorded in 2022.
  • Peak YoY movement for Retained Earnings: skyrocketed 99.96% in 2023, then plummeted 369443.72% in 2024.
  • A 5-year view of Retained Earnings shows it stood at -$2.1 million in 2021, then crashed by 110371.77% to -$2.3 billion in 2022, then dropped by 22.9% to -$2.8 billion in 2023, then skyrocketed by 99.88% to -$3.3 million in 2024, then tumbled by 90981.56% to -$3.0 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Retained Earnings were -$3.0 billion in Q4 2025, -$3.0 billion in Q3 2025, and -$3.2 billion in Q2 2025.